Our Pricing

Mounjaro Hair Loss: Understanding the Side Effects

Published on: June 03, 2026

Concerns about mounjaro hair loss UK are increasingly common as more patients begin tirzepatide treatment for weight management. Whilst hair thinning can occur during rapid weight loss, understanding the underlying mechanisms and knowing when to seek support can help you manage this temporary side effect with confidence.

Does Mounjaro Cause Hair Loss?

Mounjaro (tirzepatide) is not directly associated with hair loss as a pharmacological side effect in clinical trials [1]. However, patients using Mounjaro may experience temporary hair thinning due to the rapid weight reduction the medication facilitates. In the SURPASS trials, tirzepatide demonstrated average weight reductions of up to 22.5% over 72 weeks, and such significant metabolic changes can trigger a condition called telogen effluvium [1][2].

Telogen effluvium occurs when the body experiences physiological stress—such as rapid weight loss, nutritional changes, or caloric restriction—causing hair follicles to prematurely enter the resting phase. This typically manifests 2-4 months after starting treatment and is temporary in most cases [3]. It's important to distinguish this from medication-induced alopecia, which Mounjaro does not cause through its GIP/GLP-1 receptor mechanism.

Why Rapid Weight Loss Triggers Hair Thinning

The hair growth cycle consists of three phases: anagen (growth), catagen (transition), and telogen (resting). During periods of metabolic stress or nutritional deficit, a higher proportion of follicles shift into telogen, resulting in noticeable shedding several months later [3]. This mechanism is identical to hair loss observed after surgery, severe illness, or crash dieting.

Clinical experience shows that patients losing more than 1-2kg per week are at higher risk of telogen effluvium. Mounjaro's efficacy means some patients exceed this rate, particularly in the first 12-16 weeks of treatment when dose escalation occurs and appetite suppression is most pronounced [1][2].

The Role of Nutritional Deficiencies

When patients lose weight rapidly on Mounjaro, reduced caloric intake can lead to deficiencies in essential nutrients including protein, iron, zinc, and biotin—all critical for healthy hair growth [3]. The appetite-suppressing effects of tirzepatide, whilst beneficial for weight management, may inadvertently reduce intake of nutrient-dense foods if dietary choices aren't carefully monitored.

How Common Is Mounjaro Hair Loss?

Whilst hair loss was not reported as a common adverse event in the SURPASS clinical trial programme, real-world data suggests approximately 10-25% of patients using GLP-1 receptor agonists for weight loss experience some degree of hair thinning [4]. The incidence correlates strongly with the rate and magnitude of weight reduction rather than the medication itself.

Patients who achieve greater than 15% total body weight loss appear more susceptible, as do those with pre-existing nutritional deficiencies or restrictive eating patterns. Women are disproportionately affected, likely due to hormonal factors and lower baseline iron stores [4]. Most cases resolve spontaneously within 6-9 months once weight stabilises and nutritional status improves, though regrowth timelines vary individually.

Managing Hair Loss During Mounjaro Treatment

Many UK prescribers recommend a comprehensive multivitamin containing biotin (5,000mcg), iron (if deficiency is confirmed), vitamin D, and omega-3 fatty acids during active weight loss phases. However, supplementation should complement—not replace—a balanced diet, and patients should consult their healthcare provider before starting new supplements, particularly if taking other medications [5].

Gentle hair care practices are equally important: avoid excessive heat styling, tight hairstyles that create traction, and harsh chemical treatments. Use a wide-toothed comb on wet hair and consider a silk pillowcase to reduce friction. Whilst these measures won't prevent telogen effluvium entirely, they minimise additional stress on fragile hair during the shedding phase.

Nutritional Strategies to Support Hair Health

Ensuring adequate protein intake is paramount—aim for 1.2-1.5g per kilogram of ideal body weight daily, distributed across meals. High-quality sources include lean meats, fish, eggs, Greek yoghurt, and legumes. Iron-rich foods (red meat, spinach, lentils) paired with vitamin C enhance absorption, whilst zinc from shellfish, nuts, and seeds supports follicle function [5].

When to Seek Medical Advice About Mounjaro Hair Loss

Whilst temporary hair thinning during weight loss is generally benign, certain symptoms warrant clinical review. Contact your prescriber if you experience sudden, patchy hair loss (rather than diffuse thinning), scalp inflammation, itching, or pain, as these may indicate conditions unrelated to Mounjaro such as alopecia areata or scalp dermatitis [6].

Persistent hair loss beyond 9-12 months, particularly if weight has stabilised, should prompt investigation for underlying causes including thyroid dysfunction, iron deficiency anaemia, or hormonal imbalances. Blood tests checking ferritin, thyroid function (TSH, T4), vitamin B12, and vitamin D can identify correctable deficiencies [6]. At Cured Pharmacy, our clinical team can provide guidance during your treatment journey and arrange appropriate follow-up when needed.

Alternative Weight Loss Treatments and Hair Loss Risk

Non-injectable options like orlistat (Xenical, Alli, Orlos) work through fat absorption inhibition rather than appetite suppression, typically producing more gradual weight loss of 5-10% over 6-12 months [8]. This slower trajectory may reduce telogen effluvium risk, though fat-soluble vitamin deficiencies (A, D, E, K) can occur with orlistat and require monitoring. Your UK prescriber will help determine which treatment aligns with your weight loss goals and health priorities, subject to clinical suitability.

Comparing GLP-1 Medications

Similar hair thinning patterns have been reported with other GLP-1 receptor agonists including semaglutide (Wegovy) and liraglutide (Saxenda), reinforcing that the effect relates to weight loss velocity rather than specific drug properties [7]. Patients switching between these medications should not expect different hair-related outcomes unless weight loss rate changes significantly.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
3. Harrison, S., & Bergfeld, W. (2009). Diffuse hair loss: its triggers and management. Cleveland Clinic Journal of Medicine, 76(6), 361–367. https://doi.org/10.3949/ccjm.76a.08080 [accessed 13 August 2026]
4. Fabbrocini, G., Cantelli, M., Masarà, A., et al. (2018). Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal of Women's Dermatology, 4(4), 203–211. https://doi.org/10.1016/j.ijwd.2018.05.001 [accessed 13 August 2026]
5. Almohanna, H. M., Ahmed, A. A., Tsatalis, J. P., & Tosti, A. (2019). The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatology and Therapy, 9(1), 51–70. https://doi.org/10.1007/s13555-018-0278-6 [accessed 13 August 2026]
6. Malkud, S. (2015). Telogen Effluvium: A Review. Journal of Clinical and Diagnostic Research, 9(9), WE01–WE03. https://doi.org/10.7860/JCDR/2015/15219.6492 [accessed 13 August 2026]
7. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
8. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.